Peptipedia
HormonalFDA ApprovedFDA Approved

Lanreotide

Also known as Somatuline, Somatuline Depot

A somatostatin analog that binds preferentially to SST2 and SST5 receptors for treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors.

FDA Approved - Acromegaly and GEP-NETs
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

60-120 mg every 4 weeks

Frequency

Every 4 weeks

Duration

Long-term / chronic use

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 60-120 mg every 4 weeks via Deep subcutaneous injection, Every 4 weeks. Dose range: 60-120 mg every 4 weeks. Duration: Long-term / chronic use.

Timing & Administration

Administer via Deep subcutaneous injection. Frequency: Every 4 weeks.

Mechanism of Action

Binds preferentially to SST2 and SST5 somatostatin receptors. Inhibits GH secretion, reduces IGF-1 levels, and has antiproliferative effects on neuroendocrine tumor cells.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Acromegaly and GEP-NETs.

Side Effects & Safety

Important Warnings

  • Noninferior to octreotide for acromegaly
Diarrhea
abdominal pain
nausea
injection site reactions
gallstones
hyperglycemia/hypoglycemia
bradycardia

References

No references available.

Related Peptides

Browse all →
OxytocinHormonal

A naturally occurring peptide hormone essential for social bonding, childbirth, and lactation. Under investigation for autism, anxiety, and social disorders.

View profile
GonadorelinHormonal

A synthetic version of gonadotropin-releasing hormone used diagnostically and therapeutically for reproductive conditions.

View profile
LeuprolideHormonal

A GnRH agonist suppressing testosterone and estrogen production, approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

View profile